comparemela.com

Latest Breaking News On - Veeva vault clinical - Page 3 : comparemela.com

Cloud Stocks: Veeva Steps Up Its Consulting Engine

Veeva (NYSE: VEEV) recently reported its first quarter results that continued to surpass all market expectations. The market was pleased with its performance, and the stock rallied 7% in the after-hours trading session. Veeva's Financials Veeva's Q1 revenues grew 4% to $526.3 million, ahead of the Street's forecast by 2.1%. On an adjusted basis, EPS was $0.91, surpassing the Street's estimates of $0.79. By segment, revenues from subscription services grew 3% to $414.5 million. Professional services revenues grew 9% to $111.78 million. For the second quarter, Veeva forecast revenues of $580-$582 million and an adjusted EPS of $1.12-$1.13. The market was looking for revenues of $577.71 million and an EPS of $1.05. Veeva expects to end the current year with revenues of $2.36-$2.37 billion and an EPS of $4.59. The market was looking for revenues of $2.35 billion and an adjusted EPS of $4.32. Veeva's Product Growth Recently, Veeva announced its partnership with UCB

Lotus Clinical Research Expands Partnership with Veeva to Accelerate Clinical Trials

Lotus Clinical Research Expands Partnership with Veeva to Accelerate Clinical TrialsFast-growing CRO utilizes Veeva Vault Clinical Suite to substantially decrease startup timeNEW PROVIDENCE, NJ and BARCELONA, Spain — 30 May 2023 — Veeva Systems (NYSE: VEEV) today announced that Lotus Clinical Research ex.

Lotus Clinical Research Expands Partnership with Veeva to Accelerate Clinical Trials

Veranex Accelerating Clinical Trials with Veeva Vault CDMS – Padovanews

Veranex Accelerating Clinical Trials with Veeva Vault CDMS – Padovanews
padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.